Diurnal Group PLC - Cardiff, Wales-based pharmaceutical company - Swiss marketing and distribution partner EffRx Pharmaceuticals has submitted a market authorisation application to Swissmedic for the registration of Alkindi in Switzerland.
Alkindi is used a treatment for paediatric adrenal insufficiency, which is characterised by deficiency in the hormone cortisol. Symptoms include chronic fatigue and there is a risk of adrenal crisis and death.
Current stock price: 63.00 pence
Year-to-date change: more than doubled from 27.97p
By Dayo Laniyan; dayolaniyan@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.